alexa PARADIGM-HF Trial and its Important Clinical Meanings | OMICS International | Abstract
ISSN: 2329-9517

Journal of Cardiovascular Diseases & Diagnosis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

PARADIGM-HF Trial and its Important Clinical Meanings

Jin-lai Liu*
Department of cardiology, The Third Affiliated Hospital, SUN Yat-sun University, Guangzhou 510630, China
Corresponding Author : Jin-lai Liu
Department of cardiology
The Third Affiliated Hospital
SUN Yat-sun University
Guangzhou 510630, China
E-mail: [email protected]
Received: May 26, 2015; Accepted: June 23, 2015; Published: June 25, 2015
Citation: Liu JL (2015) PARADIGM-HF Trial and its Important Clinical Meanings. J Cardiovasc Dis Diagn 3: 205. doi: 10.4172/2329-9517.1000205
Copyright: © 2015 Liu JL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Abstract

ACEi/ARB and ß blocker and aldosterone antagonist have been a gold standard for treating chronic heart failure with reduced ejection fraction (HFrEF). The paper described simply the PARADIGM-HF study (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in HF trial), and the results showed that compared to enalapril, LCZ69(ARNi) significantly reduced the primary endpoint (cardiovascular death or hospitalization for HF) [HR0.80 (95% CI 0.73-0.87)?P<0.001; NNT 21], cardiovascular death [HR0.80 (95% CI 0.71-0.89)?P<0.001; NNT 31], hospitalization for HF [HR0.79 (95% CI 0.71-0.89)?P<0.001; NNT 36], and death from any cause [HR0.84 (95% CI 0.76-0.93), P<0.001; NNT 36]. LCZ696 was well tolerated. The PARADIGM-HF study has an important clinical significance and would change the pattern of HF treatment in the future.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]nline.com

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7